Skip to main content

Guardian Pharmacy Services, Inc.

For the period ended Mar 31, 2025. Filed May 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

GRDN$47.02+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations

Three Months Ended March 31,
(In thousands, except share and per share amounts)20242025
Revenues$275,410$329,308
Cost of goods sold220,309264,959
Gross profit55,10164,349
Selling, general, and administrative expenses47,16851,344
Operating income7,93313,005
Other expenses (income):
Interest expense765170
Other expense (income), net73(271)
Total other expenses (income)838(101)
Income before income taxes7,09513,106
Provision for income taxes—3,833
Net income7,0959,273
Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization2,786—
Less net income (loss) attributable to non-controlling interests4,309(175)
Net income attributable to Guardian Pharmacy Services, Inc.$—$9,448
BasicN/A$0.15
DilutedN/A$0.15
Weighted-average Class A and Class B common shares outstanding
BasicN/A62,043,311
DilutedN/A62,914,077
1Basic and diluted net income per share of Class A and Class B common stock is applicable only for the three months ended March 31, 2025, which is the only period presented following the initial public offering (“IPO”) and related Corporate Reorganization (as defined below in Note 1 Organization and Background). See Note 6 Basic and Diluted Net Income Per Share for the number of shares used in the computation of net income per share of Class A and Class B common stock and the basis for the computation of net income per share.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.